2:30 – 3:30 pm Friday, September 4

How to Return Research Results to Patients and Families? The Children’s Oncology Group Experience (C232)

In North America, the majority of children with cancer will enroll in a clinical trial at some point during their treatment. Clinical research is rooted in the premise that the quantity and quality of human lives will be improved by carefully conducted clinical and basic research.

Read more...
Speaker:
Kimberly Pyke-Grimm, PhD RN CNS CPHON®
CNE Hours
1
2:30 – 3:30 pm Friday, September 4

Preparing Patients and Families for the Off-Therapy Transition (230)

Completion of cancer-directed therapy can be an exciting time for patients and their families but may also be anxiety provoking as they face a new set of challenges and a “new normal.” Patients may be returning to school with new needs for academic accommodations or returning to the care of their primary care provider, who may have limited experience with childhood cancer survivors.

Read more...
Speaker:
Emily Browne, DNP RN CPNP
CNE Hours
1
2:30 – 3:30 pm Friday, September 4

This is Awkward...  Having Difficult Conversations about AYA Sexual Health (227)

Sexual and reproductive health (SRH) is a key aspect of physical health, emotional health, and quality of life in adolescents and young adults (AYAs) with cancer and blood disorders both during and after treatment. AYAs increasingly identify concerns with sexual function, contraception, fertility, and psychosexual adjustment and report conversations on these topics rarely take place with providers.

Read more...
Speaker:
Stacy Whiteside, MS APRN CPON® CPNP-AC/PC 
CNE Hours
1
10:45 – 11:45 am Wednesday, September 2

Cancer Predisposition: Li-Fraumeni Syndrome in Pediatrics, Nurses Can Make A Difference in Quality of Life and Long-Term Survival Through Screening and Education (201-1)

Oncology nurses provide care for patients and families with multiple early-onset cancers. This session will review Li-Fraumeni Syndrome (LFS), a genetic cancer predisposition syndrome. It is recognized as a mutation in the TP53 gene, the most frequently mutated gene in sporadic cancers. LFS is defined as any germline mutation in the TP53 tumor suppressor gene that is passed down in an autosomal dominant pattern.

Read more...
Speaker:
Heather Meador, MSN APRN CPNP CPHON®
Whitney Throckmorton, MPAS PA-C
CNE Hours
0.5
Subscribe to this RSS feed